Acne News and Research RSS Feed - Acne News and Research

Acne is a disorder resulting from the action of hormones and other substances on the skin's oil glands (sebaceous glands) and hair follicles. These factors lead to plugged pores and outbreaks of lesions commonly called pimples or zits. Acne lesions usually occur on the face, neck, back, chest, and shoulders. Although acne is usually not a serious health threat, it can be a source of significant emotional distress. Severe acne can lead to permanent scarring.
New web-based platform launched to provide acne care to patients across Pennsylvania

New web-based platform launched to provide acne care to patients across Pennsylvania

Dr. Jamie Altman, owner and president of Aesthetic Dermatology Associates, PC, a dermatology practice based in the Philadelphia suburbs of Media and Paoli, today announced the launch of AcneCareMD.com, a secure telemedicine website designed to provide acne care to patients across Pennsylvania via a web-based platform. [More]
New targeted therapy promises to reduce frequency and intensity of breakouts

New targeted therapy promises to reduce frequency and intensity of breakouts

Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples. [More]
Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis. [More]
Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. [More]
Acne patients not getting medications prescribed by their dermatologists

Acne patients not getting medications prescribed by their dermatologists

Medicine obviously can't do much good if it sits on a pharmacy shelf. Yet more than one-quarter of the acne patients surveyed by Wake Forest Baptist Medical Center researchers didn't get medications prescribed by their dermatologists. [More]
Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

A new study by researchers at Brigham and Women's Hospital has found that for young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense. [More]
Canfield to become sole supplier of PRIMOS family of 3D optical systems worldwide

Canfield to become sole supplier of PRIMOS family of 3D optical systems worldwide

Demonstrating its commitment to delivering best-in-class clinical research solutions, Canfield Scientific has been named the exclusive worldwide distributor of the highly respected PRIMOS family of 3D optical systems. [More]

Alma Lasers launches Harmony XL Pro platform to address aesthetic concerns of patients

Alma Lasers, a global innovator of laser, light-based, radiofrequency and ultrasound solutions for the aesthetic and surgical markets announced the addition of the Harmony XL Pro platform to its product portfolio. [More]

Envy Medical launches world-class patented Advanced Dermalinfusion Technology

Envy Medical, Inc. launches SilkPeel3, the next generation of its world class patented Advanced Dermalinfusion Technology. Unveiled originally in 2005, SilkPeel is celebrating its 10th birthday in style with fresh features, enhanced functionality and a sleek new design. [More]
Blunted cortisol response common in non-classic CAH

Blunted cortisol response common in non-classic CAH

Nearly two-thirds of children with non-classic congenital adrenal hyperplasia have an inadequate cortisol response, report researchers. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Cipher acquires worldwide rights to three products from Astion

Cipher acquires worldwide rights to three products from Astion

Cipher Pharmaceuticals Inc. today announced it has strengthened its product pipeline by acquiring the worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharmaceutical company. [More]
FDA approves Cynosure's new 532 nm Laser Delivery System for PicoSure

FDA approves Cynosure's new 532 nm Laser Delivery System for PicoSure

Cynosure, Inc. today announced FDA 510(k) clearance of its new 532 nm Laser Delivery System for PicoSure, creating a powerful, dual-wavelength laser system for removing tattoos of all colors in fewer treatments. PicoSure, the world's first picosecond aesthetic laser, is widely recognized for its technology leadership, unmatched clinical versatility and proven performance. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by Health Canada. [More]
Providing knowledge about contraception can significantly improve use of isotretinoin

Providing knowledge about contraception can significantly improve use of isotretinoin

Providing women who take a powerful acne drug with a fact sheet about contraception while visiting the dermatologist can significantly improve their awareness of the most effective birth control options and may prevent unintended pregnancies and birth defects that can be caused by the drug, according to a University of Pittsburgh School of Medicine study published Feb. 4 in the journal JAMA Dermatology. [More]

NYU Langone dermatologist offers tips to prevent ingrown hair

Ingrown hair, also known as "razor bumps," are a common skin condition, particularly in people whose hair has the tendency to curl back or grow sideways in a hair follicle. [More]

Sebacia reports positive clinical results from two independent studies in people with acne

Sebacia, Inc., a company dedicated to delivering breakthrough topical treatments to advance dermatology, has announced the presentation of positive clinical results from two independent studies conducted in Europeinvestigating the use of Sebacia gold microparticles to treat acne. [More]
Manchester researcher discover novel way to eradicate cancer stem cells

Manchester researcher discover novel way to eradicate cancer stem cells

A way to eradicate cancer stem cells, using the side-effects of commonly used antibiotics, has been discovered by a University of Manchester researcher following a conversation with his young daughter. [More]
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. [More]
Advertisement